For the full year of fiscal 2023, Lightspeed now expects an Adjusted EBITDA loss1 of approximately ($37) million, improved from previously-established outlook of approximately ($40) million. The Company now expects annual revenue to come in at the low end of the previously established outlook of $730 – $740 million (or approximately $740 million – $750 million on a constant currency basis1).
Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed eRapa In Familial Adenomatous Polyposis Scheduled For Presentation At The 2024 Digestive Disease Week Annual Meeting; Reports Overall 83% Non-Progression Rate At 6 Mo…
Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for
